Search

Your search keyword '"Mascarenhas, Leo"' showing total 534 results
Start Over Author "Mascarenhas, Leo"
534 results on '"Mascarenhas, Leo"'

103. The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas

Author

DuBois, Steven G., Laetsch, Theodore W., Federman, Noah, Turpin, Brian K., Albert, Catherine M., Nagasubramanian, Ramamoorthy, Anderson, Megan E., Davis, Jessica L., Qamoos, Hope E., Reynolds, Mark E., Cruickshank, Scott, Cox, Michael C., Hawkins, Douglas S., Mascarenhas, Leo, and Pappo, Alberto S.

Subjects
Male, infantile fibrosarcoma, sarcoma, tropomyosin receptor kinase (TRK) fusion, Oncogene Proteins, Fusion, Fibrosarcoma, Oncology and Carcinogenesis, Soft Tissue Neoplasms, Discipline, surgery, Rare Diseases, neurotrophic receptor tyrosine kinase (NTRK), Clinical Research, Humans, Oncology & Carcinogenesis, Receptor, trkA, Fusion, Child, Preschool, larotrectinib, Cancer, Oncogene Proteins, Pediatric, Infant, Newborn, Infant, Evaluation of treatments and therapeutic interventions, Original Articles, Newborn, Neoadjuvant Therapy, pediatric, Pyrimidines, Treatment Outcome, local control, Pediatric Oncology, Child, Preschool, trkA, 6.1 Pharmaceuticals, neurotrophic receptor tyrosine kinase, Disease Progression, Public Health and Health Services, Pyrazoles, Original Article, Female, Patient Safety, Receptor
Abstract

Background The highly selective oral tropomyosin receptor kinase (TRK) inhibitor larotrectinib has demonstrated significant activity in adult and pediatric TRK fusion cancers. In the current study, the authors describe the clinical course of children with locally advanced TRK fusion sarcoma who were treated preoperatively with larotrectinib and underwent subsequent surgical resection. Methods A total of 24 children were treated on a pediatric phase 1 trial of larotrectinib (ClinicalTrials.gov identifier NCT02637687). Five children who had a documented TRK fusion sarcoma and underwent surgical resection were included in the current analysis. Tumor response (Response Evaluation Criteria In Solid Tumors [RECIST] version 1.1) and surgical outcomes were collected prospectively. Results A total of 5 patients (median age, 2 years; range, 0.4‐12 years) had locally advanced infantile fibrosarcoma (3 patients) or soft‐tissue sarcoma (2 patients). Four patients had disease that was refractory to standard therapy. All 5 patients achieved a partial response to larotrectinib by version 1.1 of RECIST and underwent surgical resection after a median of 6 cycles (range, 4‐9 cycles) of treatment. Surgical resections were R0 (negative resection margins with no tumor at the inked resection margin) in 3 patients, R1 (microscopic residual tumor at the resection margin) in 1 patient, and R2 (macroscopic residual tumor at the resection margin) in 1 patient. Three patients achieved complete (2 patients) or near‐complete (>98% treatment effect; 1 patient) pathologic responses. These patients remained in follow‐up and were no longer receiving larotrectinib for a minimum of 7 to 15 months postoperatively. Two patients had viable tumor at the time of surgical resection and positive resection margins and continued to receive adjuvant larotrectinib. No patients experienced postoperative complications or wound healing issues. Conclusions Children with locally advanced TRK fusion sarcomas may proceed to surgical resection after treatment with the selective TRK inhibitor larotrectinib, thereby sparing them the potentially significant morbidity noted with current approaches. These results support the evaluation of larotrectinib as presurgical therapy in children with newly diagnosed TRK fusion sarcomas., Children with locally advanced tropomyosin receptor kinase (TRK) fusion sarcomas may proceed to surgical resection after neoadjuvant treatment with the selective oral TRK inhibitor larotrectinib, sparing them the potentially significant morbidity noted with current approaches. The results of the current study support the further evaluation of larotrectinib as neoadjuvant therapy in children with newly diagnosed TRK fusion sarcomas.

Published
2018

104. Randomized Phase II Trial of Bevacizumab or Temsirolimus in Combination With Chemotherapy for First Relapse Rhabdomyosarcoma: A Report From the Children’s Oncology Group

Author

Mascarenhas, Leo, primary, Chi, Yueh-Yun, additional, Hingorani, Pooja, additional, Anderson, James R., additional, Lyden, Elizabeth R., additional, Rodeberg, David A., additional, Indelicato, Daniel J., additional, Kao, Simon C., additional, Dasgupta, Roshni, additional, Spunt, Sheri L., additional, Meyer, William H., additional, and Hawkins, Douglas S., additional

Published
2019
Full Text
View/download PDF

105. GENE-50. SWI/SNF COMPLEX HETEROGENEITY RELATES WITH POLYPHENOTYPIC DIFFERENTIATION, PROGNOSIS AND IMMUNE RESPONSE IN RHABDOID TUMORS

Author

Venneti, Sriram, primary, Panwalkar, Pooja, additional, Pratt, Drew, additional, Chung, Chan, additional, Dang, Derek, additional, Lee, Paul, additional, Martinez, Daniel, additional, Bayliss, Jill, additional, Smith, Kyle, additional, Adam, Mike, additional, Potter, Steve, additional, Northcott, Paul, additional, Mascarenhas, Leo, additional, Shows, Jared, additional, Pawel, Bruce, additional, Margol, Ashley, additional, Huang, Annie, additional, and Judkins, Alexander, additional

Published
2019
Full Text
View/download PDF

106. Abstract CT109: A Phase I dose escalation and expansion study of seclidemstat (SP-2577) a first-in class reversible LSD1 inhibitor for patients with relapsed or refractory Ewing sarcoma

Author

Reed, Damon, primary, DuBois, Steven G., additional, Gorlick, Richard, additional, Mascarenhas, Leo, additional, Harrison, Douglas, additional, Metts, Jonathan, additional, Lessnick, Stephen L., additional, Crompton, Brian D., additional, Loeb, David M., additional, Hernandez, Rose, additional, Larson, Jeff, additional, and Stenehjem, David D., additional

Published
2019
Full Text
View/download PDF

107. Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma

Author

Davis, Lara E., primary, Bolejack, Vanessa, additional, Ryan, Christopher W., additional, Ganjoo, Kristen N., additional, Loggers, Elizabeth T., additional, Chawla, Sant, additional, Agulnik, Mark, additional, Livingston, Michael B., additional, Reed, Damon, additional, Keedy, Vicky, additional, Rushing, Daniel, additional, Okuno, Scott, additional, Reinke, Denise K., additional, Riedel, Richard F., additional, Attia, Steven, additional, Mascarenhas, Leo, additional, and Maki, Robert G., additional

Published
2019
Full Text
View/download PDF

108. A phase I study of LOXO-292, a highly selective RET inhibitor, in pediatric patients with RET-altered cancers.

Author

DuBois, Steven G., primary, Albert, Catherine Michelle, additional, Mascarenhas, Leo, additional, Laetsch, Theodore Willis, additional, van Tilburg, Cornelis Martinus, additional, Potter, Samara L, additional, Turpin, Brian, additional, Glade Bender, Julia Lynne, additional, Spunt, Sheri L., additional, Hladun, Raquel, additional, Casanova, Michela, additional, Ziegler, David Simon, additional, Morgenstern, Daniel A., additional, Eary, Todd, additional, Ibabekci, Shannon, additional, Qamoos, Hope, additional, Rothenberg, Stephen M., additional, Cox, Michael Craig, additional, Balis, Frank M., additional, and Pappo, Alberto S., additional

Published
2019
Full Text
View/download PDF

109. A randomized trial of a mercaptopurine (6MP) adherence-enhancing intervention in children with acute lymphoblastic leukemia (ALL): A COG ACCL1033 study.

Author

Bhatia, Smita, primary, Hageman, Lindsey, additional, Chen, Yanjun, additional, Wong, Florence Lennie, additional, Mascarenhas, Leo, additional, Freyer, David Robert, additional, Mba, Nkechi, additional, Aristizabal, Paula, additional, Walterhouse, David, additional, Lew, Glen, additional, Kempert, Pamela, additional, Russell, Thomas, additional, McNall-Knapp, Rene, additional, Jacobs, Shana S., additional, Dang, Ha, additional, Raetz, Elizabeth A., additional, Relling, Mary V., additional, and Landier, Wendy, additional

Published
2019
Full Text
View/download PDF

110. Patient-reported outcomes from two global multicenter clinical trials of children and adults with tropomyosin receptor kinase (TRK) fusion cancer receiving larotrectinib.

Author

Kummar, Shivaani, primary, Mascarenhas, Leo, additional, Geoerger, Birgit, additional, Turpin, Brian, additional, Cox, Michael Craig, additional, Yu, Sandie, additional, Nanda, Shivani, additional, Hiemeyer, Florian, additional, Keating, Karen N, additional, Chirila, Costel, additional, Gnanasakthy, Ari, additional, Davenport, Eric, additional, Hong, David S., additional, and Drilon, Alexander E., additional

Published
2019
Full Text
View/download PDF

111. Larotrectinib efficacy and safety in pediatric TRK fusion cancer patients.

Author

van Tilburg, Cornelis Martinus, primary, DuBois, Steven G., additional, Albert, Catherine Michelle, additional, Federman, Noah, additional, Nagasubramanian, Ramamoorthy, additional, Geoerger, Birgit, additional, Orbach, Daniel, additional, Bielack, Stefan S., additional, Shukla, Neerav Narendra, additional, Turpin, Brian, additional, Casanova, Michela, additional, Spunt, Sheri L., additional, Qamoos, Hope, additional, Nanda, Shivani, additional, Childs, Barrett H., additional, Cox, Michael Craig, additional, Pappo, Alberto S., additional, Laetsch, Theodore Willis, additional, and Mascarenhas, Leo, additional

Published
2019
Full Text
View/download PDF

112. Risk‐based treatment for patients with first relapse or progression of rhabdomyosarcoma: A report from the Children's Oncology Group

Author

Mascarenhas, Leo, primary, Lyden, Elizabeth R., additional, Breitfeld, Philip P., additional, Walterhouse, David O., additional, Donaldson, Sarah S., additional, Rodeberg, David A., additional, Parham, David M., additional, Anderson, James R., additional, Meyer, William H., additional, and Hawkins, Douglas S., additional

Published
2019
Full Text
View/download PDF

113. SARC025 arms 1 and 2: A phase 1 study of the poly(ADP‐ribose) polymerase inhibitor niraparib with temozolomide or irinotecan in patients with advanced Ewing sarcoma.

Author

Chugh, Rashmi, Ballman, Karla V., Helman, Lee J., Patel, Shreyaskumar, Whelan, Jeremy S., Widemann, Brigitte, Lu, Yao, Hawkins, Douglas S., Mascarenhas, Leo, Glod, John W., Ji, Jiuping, Zhang, Yiping, Reinke, Denise, and Strauss, Sandra J.

Subjects
EWING'S sarcoma, ADENOSINE diphosphate ribose, POLY ADP ribose, IRINOTECAN, TEMOZOLOMIDE, ALANINE aminotransferase
Abstract

Background: In preclinical Ewing sarcoma (ES) models, poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors were identified as a potential therapeutic strategy with synergy in combination with cytotoxic agents. This study evaluated the safety and dosing of the PARP1/2 inhibitor niraparib (NIR) with temozolomide (TMZ; arm 1) or irinotecan (IRN; arm 2) in patients with pretreated ES. Methods: Eligible patients in arm 1 received continuous NIR daily and escalating TMZ (days 2‐6 [D2‐6]) in cohort A. Subsequent patients received intermittent NIR dosing (cohort B), with TMZ re‐escalation in cohort C. In arm 2, patients were assigned to NIR (days 1‐7 [D1‐7]) and escalating doses of IRN (D2‐6). Results: From July 2014 to May 2018, 29 eligible patients (23 males and 6 females) were enrolled in arms 1 and 2, which had 7 dose levels combined. Five patients experienced at least 1 dose‐limiting toxicity (DLT) in arm 1 (grade 4 [G4] neutropenia for >7 days or G4 thrombocytopenia), and 3 patients experienced at least 1 DLT in arm 2 (grade 3 [G3] colitis, G3 anorexia, or G3 alanine aminotransferase elevation). The maximum tolerated dose was NIR at 200 mg every day on D1‐7 plus TMZ at 30 mg/m2 every day on D2‐6 (arm 1) or NIR at 100 mg every day on D1‐7 plus IRN at 20 mg/m2 every day on D2‐6 (arm 2). One confirmed partial response was observed in arm 2; the median progression‐free survival was 9.0 weeks (95% CI, 7.0‐10.1 weeks) and 16.3 weeks (95% CI, 5.1‐69.7 weeks) in arms 1 and 2, respectively. The median decrease in tumor poly(ADP‐ribose) activity was 89% (range, 83%‐98%). Conclusions: The combination of NIR and TMZ or IRN was tolerable, but at lower doses in comparison with conventional cytotoxic combinations. A triple‐combination study of NIR, IRN, and TMZ has commenced. Preclinical evaluations have identified the EWS‐FLI1 translocation, pathognomonic of Ewing sarcoma, as a predictive factor of response to poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors with synergistic cell death in vivo with DNA damaging agents. This phase 1 study examines the dosing and safety of a combination of the PARP inhibitor niraparib with temozolomide or irinotecan. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

114. Survival outcomes of patients with localized FOXO1 fusion‐positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.

Author

Heske, Christine M., Chi, Yueh‐Yun, Venkatramani, Rajkumar, Li, Minjie, Arnold, Michael A., Dasgupta, Roshni, Hiniker, Susan M., Hawkins, Douglas S., and Mascarenhas, Leo

Subjects
CLINICAL trial registries, SARCOMA, SURVIVAL analysis (Biometry), RHABDOMYOSARCOMA, PROGNOSIS
Abstract

Background: The objective of this analysis was to evaluate the clinical factors influencing survival outcomes in patients with localized (clinical group I‐III), FOXO1 fusion‐positive rhabdomyosarcoma (RMS). Methods: Patients with confirmed FOXO1 fusion‐positive RMS who were enrolled on 3 completed clinical trials for localized RMS were included in the analytic cohort. Outcomes were analyzed using the Kaplan‐Meier method to estimate event‐free survival (EFS) and overall survival (OS), and the curves were compared using the log‐rank test. A Cox proportional hazards regression model was used to perform multivariate analysis of prognostic factors that were significant in the univariate analysis. Results: The estimated 4‐year EFS and OS of 269 patients with localized, FOXO1 fusion‐positive RMS was 53% (95% CI, 47%‐59%) and 69% (95% CI, 63%‐74%), respectively. Univariate analysis revealed that several known favorable clinical characteristics, including age at diagnosis between 1 and 9 years, complete surgical resection, tumor size ≤5 cm, favorable tumor site, absence of lymph node involvement, confinement to the anatomic site of origin, and PAX7‐FOXO1 fusion, were associated with improved outcomes. Multivariate analysis identified older age (≥10 years) and large tumor size (>5 cm) as independent, adverse prognostic factors for EFS within this population, and patients who had both adverse features experienced substantially inferior outcomes. Conclusions: Patients with localized, FOXO1 fusion‐positive RMS can be further risk stratified based on clinical features at diagnosis, and older patients with large primary tumors have the poorest prognosis. The effects of clinical features on outcomes are analyzed in patients with localized, FOXO1 fusion‐positive rhabdomyosarcoma (RMS) treated on recent Children's Oncology Group studies. Two clinical features, older age (≥10 years) and large tumor size (>5 cm), are identified as independent adverse prognostic indicators for relapse in this patient group, and patients who have both features experience outcomes similar to those of patients who have RMS with distant metastases. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

115. Alveolar rhabdomyosarcoma with regional nodal involvement: Results of a combined analysis from two cooperative groups.

Author

Gallego, Soledad, Chi, Yueh‐Yun, De Salvo, Gian Luca, Li, Minjie, Merks, Johannes H.M., Rodeberg, David A., Scheltinga, Sheila Terwisscha, Mascarenhas, Leo, Orbach, Daniel, Jenney, Meriel, Million, Lynn, Minard‐Colin, Veronique, Wolden, Suzanne, Zanetti, Ilaria, Parham, David M., Mandeville, Henry, Venkatramani, Rajkumar, Bisogno, Gianni, and Hawkins, Douglas S.

Published
2021
Full Text
View/download PDF

116. Metabolic response as assessed by 18F‐fluorodeoxyglucose positron emission tomography‐computed tomography does not predict outcome in patients with intermediate‐ or high‐risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee

Author

Harrison, Douglas J., Chi, Yueh‐Yun, Tian, Jing, Hingorani, Pooja, Mascarenhas, Leo, McCowage, Geoffrey B., Weigel, Brenda J., Venkatramani, Rajkumar, Wolden, Suzanne L., Yock, Torunn I., Rodeberg, David A., Hayes‐Jordan, Andrea A., Teot, Lisa A., Spunt, Sheri L., Meyer, William H., Hawkins, Douglas S., Shulkin, Barry L., and Parisi, Marguerite T.

Subjects
POSITRON emission tomography computed tomography, SARCOMA, RHABDOMYOSARCOMA, PROPORTIONAL hazards models
Abstract

Background: Strategies to optimize management in rhabdomyosarcoma (RMS) include risk stratification to assign therapy aiming to minimize treatment morbidity yet improve outcomes. This analysis evaluated the relationship between complete metabolic response (CMR) as assessed by 18F‐fluorodeoxyglucose positron emission tomography‐computed tomography (FDG‐PET) imaging and event‐free survival (EFS) in intermediate‐risk (IR) and high‐risk (HR) RMS patients. Methods: FDG‐PET imaging characteristics, including assessment of CMR and maximum standard uptake values (SUVmax) of the primary tumor, were evaluated by central review. Institutional reports of SUVmax were used when SUVmax values could not be determined by central review. One hundred and thirty IR and 105 HR patients had FDG‐PET scans submitted for central review or had SUVmax data available from institutional report at any time point. A Cox proportional hazards regression model was used to evaluate the relationship between these parameters and EFS. Results: SUVmax at study entry did not correlate with EFS for IR (p = 0.32) or HR (p = 0.86) patients. Compared to patients who did not achieve a CMR, EFS was not superior for IR patients who achieved a CMR at weeks 4 (p = 0.66) or 15 (p = 0.46), nor for HR patients who achieved CMR at week 6 (p = 0.75) or 19 (p = 0.28). Change in SUVmax at week 4 (p = 0.21) or 15 (p = 0.91) for IR patients or at week 6 (p = 0.75) or 19 (p = 0.61) for HR patients did not correlate with EFS. Conclusion: Based on these data, FDG‐PET does not appear to predict EFS in IR or HR‐RMS. It remains to be determined whether FDG‐PET has a role in predicting survival outcomes in other RMS subpopulations. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

118. Abstract PR07: A pediatric phase 1 study of larotrectinib, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family: An updated analysis

Author

Turpin, Brian, primary, Albert, Catherine M., additional, Mascarenhas, Leo, additional, Federman, Noah, additional, Nagasubramanian, Ramamoorthy, additional, Reynolds, Mark, additional, Smith, Steven, additional, Cruickshank, Scott, additional, Cox, Michael C., additional, Pappo, Alberto S., additional, Hawkins, Douglas S., additional, DuBois, Steven G., additional, and Laetsch, Theodore W., additional

Published
2018
Full Text
View/download PDF

119. 12. Pediatric oncology testing in the front-line setting: Utility of the CHLA OncoKids panel

Author

Biegel, Jaclyn, primary, Raca, Gordana, additional, Ji, Jianling, additional, Cotter, Jennifer, additional, Shimada, Hiroyuki, additional, Zhou, Shengmei, additional, Shillingford, Nicholas, additional, Warren, Mika, additional, Hawes, Debra, additional, Tian, Di, additional, Oberley, Matthew, additional, Navid, Fariba, additional, Shah, Rachana, additional, Thomas, Stephanie, additional, Robison, Nathan, additional, Margol, Ashley, additional, Bhojwani, Deepa, additional, Dhall, Girish, additional, Mascarenhas, Leo, additional, Parham, David, additional, Judkins, Alexander, additional, Triche, Tim, additional, and Hiemenz, Matthew, additional

Published
2018
Full Text
View/download PDF

120. Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children’s Oncology Group

Author

Hawkins, Douglas S., primary, Chi, Yueh-Yun, additional, Anderson, James R., additional, Tian, Jing, additional, Arndt, Carola A.S., additional, Bomgaars, Lisa, additional, Donaldson, Sarah S., additional, Hayes-Jordan, Andrea, additional, Mascarenhas, Leo, additional, McCarville, Mary Beth, additional, McCune, Jeannine S., additional, McCowage, Geoff, additional, Million, Lynn, additional, Morris, Carol D., additional, Parham, David M., additional, Rodeberg, David A., additional, Rudzinski, Erin R., additional, Shnorhavorian, Margarett, additional, Spunt, Sheri L., additional, Skapek, Stephen X., additional, Teot, Lisa A., additional, Wolden, Suzanne, additional, Yock, Torunn I., additional, and Meyer, William H., additional

Published
2018
Full Text
View/download PDF

121. A randomized, double-blind, placebo-controlled, phase II study of regorafenib vs placebo in advanced/metastatic, treatment-refractory liposarcoma: results from the SARC024 study.

Author

Riedel, Richard F., primary, Ballman, Karla V., additional, Lu, Yao, additional, Attia, Steven, additional, Loggers, Elizabeth Trice, additional, Ganjoo, Kristen N., additional, Livingston, Michael B., additional, Chow, Warren Allen, additional, Wright, Jennifer A., additional, Ward, John Harris, additional, Rushing, Daniel A., additional, Okuno, Scott H., additional, Reed, Damon R., additional, Liebner, David A., additional, Keedy, Vicki Leigh, additional, Mascarenhas, Leo, additional, Davis, Lara Emily, additional, Ryan, Christopher W., additional, Reinke, Denise K., additional, and Maki, Robert G., additional

Published
2018
Full Text
View/download PDF

122. Phase 1 study of olaratumab as monotherapy and in combination with doxorubicin, vincristine/irinotecan, or high-dose ifosfamide in pediatric patients with relapsed or refractory solid tumors: Part A results.

Author

DuBois, Steven G., primary, Weigel, Brenda, additional, Laetsch, Theodore Willis, additional, Macy, Margaret, additional, Levy, Donna Elise, additional, Mo, Gary, additional, Wright, Jennifer A., additional, and Mascarenhas, Leo, additional

Published
2018
Full Text
View/download PDF

123. Efficacy of Larotrectinib inTRKFusion–Positive Cancers in Adults and Children

Author

Drilon, Alexander, primary, Laetsch, Theodore W., additional, Kummar, Shivaani, additional, DuBois, Steven G., additional, Lassen, Ulrik N., additional, Demetri, George D., additional, Nathenson, Michael, additional, Doebele, Robert C., additional, Farago, Anna F., additional, Pappo, Alberto S., additional, Turpin, Brian, additional, Dowlati, Afshin, additional, Brose, Marcia S., additional, Mascarenhas, Leo, additional, Federman, Noah, additional, Berlin, Jordan, additional, El-Deiry, Wafik S., additional, Baik, Christina, additional, Deeken, John, additional, Boni, Valentina, additional, Nagasubramanian, Ramamoorthy, additional, Taylor, Matthew, additional, Rudzinski, Erin R., additional, Meric-Bernstam, Funda, additional, Sohal, Davendra P.S., additional, Ma, Patrick C., additional, Raez, Luis E., additional, Hechtman, Jaclyn F., additional, Benayed, Ryma, additional, Ladanyi, Marc, additional, Tuch, Brian B., additional, Ebata, Kevin, additional, Cruickshank, Scott, additional, Ku, Nora C., additional, Cox, Michael C., additional, Hawkins, Douglas S., additional, Hong, David S., additional, and Hyman, David M., additional

Published
2018
Full Text
View/download PDF

124. Clinical and Genetic Risk Prediction of Subsequent CNS Tumors in Survivors of Childhood Cancer: A Report From the COG ALTE03N1 Study

Author

Wang, Xuexia, primary, Sun, Can-Lan, additional, Hageman, Lindsey, additional, Smith, Kandice, additional, Singh, Purnima, additional, Desai, Sunil, additional, Hawkins, Douglas S., additional, Hudson, Melissa M., additional, Mascarenhas, Leo, additional, Neglia, Joseph P., additional, Oeffinger, Kevin C., additional, Ritchey, A. Kim, additional, Robison, Leslie L., additional, Villaluna, Doojduen, additional, Landier, Wendy, additional, and Bhatia, Smita, additional

Published
2017
Full Text
View/download PDF

126. Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Children’s Oncology Group Study AALL03N1

Author

Landier, Wendy, primary, Hageman, Lindsey, additional, Chen, Yanjun, additional, Kornegay, Nancy, additional, Evans, William E., additional, Bostrom, Bruce C., additional, Casillas, Jacqueline, additional, Dickens, David S., additional, Angiolillo, Anne L., additional, Lew, Glen, additional, Maloney, Kelly W., additional, Mascarenhas, Leo, additional, Ritchey, A. Kim, additional, Termuhlen, Amanda M., additional, Carroll, William L., additional, Relling, Mary V., additional, Wong, F. Lennie, additional, and Bhatia, Smita, additional

Published
2017
Full Text
View/download PDF

127. A phase 1, open-label, dose-escalation study of olaratumab as a single agent and in combination with doxorubicin, vincristine/irinotecan, or high-dose ifosfamide in pediatric patients with relapsed or refractory solid tumors.

Author

Mascarenhas, Leo, primary, Tai, Datchen Fritz, additional, Bishop, Michael William, additional, DuBois, Steven G., additional, Laetsch, Theodore Willis, additional, Levy, Donna Elise, additional, and Pillay, Sada, additional

Published
2017
Full Text
View/download PDF

128. Measuring mercaptopurine (6MP) adherence using red cell 6MP metabolite levels in children with acute lymphoblastic leukemia (ALL): A COG AALL03N1 study.

Author

Hoppmann, Anna Lynn, primary, Hill, Torrey, additional, Chen, Yanjun, additional, Landier, Wendy, additional, Hageman, Lindsey, additional, Evans, William E., additional, Angiolillo, Anne L., additional, Bostrom, Bruce C., additional, Casillas, Jacqueline N., additional, Lew, Glen, additional, Maloney, Kelly W., additional, Mascarenhas, Leo, additional, Ritchey, A. Kim, additional, Termuhlen, Amanda M., additional, Carroll, William L., additional, Wong, Florence Lennie, additional, Relling, Mary V., additional, and Bhatia, Smita, additional

Published
2017
Full Text
View/download PDF

129. A pediatric phase I study of larotrectinib, a highly selective inhibitor of the tropomyosin receptor kinase (TRK) family.

Author

Laetsch, Theodore Willis, primary, DuBois, Steven G., additional, Nagasubramanian, Ramamoorthy, additional, Turpin, Brian, additional, Mascarenhas, Leo, additional, Federman, Noah, additional, Reynolds, Mark, additional, Smith, Steven, additional, Cruickshank, Scott, additional, Cox, Michael Craig, additional, Pappo, Alberto S., additional, and Hawkins, Douglas S., additional

Published
2017
Full Text
View/download PDF

132. Pilot study of adding vincristine, topotecan, and cyclophosphamide to interval compressed chemotherapy in newly diagnosed patients with localized Ewing sarcoma: A report from the Children's Oncology Group

Author

Mascarenhas, Leo, Felgenhauer, Judy. L., Bond, Mason C., Villaluna, Doojduen, Femino, J. Dominic, Laack, Nadia. N., Ranganathan, Sarangarajan, Meyer, James, Womer, Richard B., Gorlick, Richard, Krailo, Mark D., and Marina, Neyssa

Subjects
Male, Bone Neoplasms, Pilot Projects, Soft Tissue Neoplasms, Sarcoma, Ewing, Article, Drug Administration Schedule, Doxorubicin, Vincristine, Antineoplastic Combined Chemotherapy Protocols, Humans, Female, Ifosfamide, Child, Topotecan, Cyclophosphamide, Etoposide
Abstract

The combination of topotecan and cyclophosphamide is active in relapsed Ewing sarcoma family of tumors (ESFT). The feasibility of adding these agents combined with vincristine (vincristine-topotecan-cyclophosphamide [VTc]) to standard five-drug chemotherapy with vincristine-doxorubicin-cyclophosphamide (VDC) and ifosfamide-etoposide (IE) administered in an interval-compressed (2-week instead of 3-week intervals) schedule was investigated.Newly diagnosed patients with localized ESFT31 years, with good performance status and adequate organ function were eligible. Seventeen alternating cycles of chemotherapy with VTc, VDC, and IE were administered at 2-week intervals. Local control (LC) of the primary tumor occurred following six cycles. Primary endpoints were the ability to deliver chemotherapy in an interval-compressed schedule, and the rate of grade 3 or greater nonhematologic toxicity and grade 4 hematologic toxicity, which delayed chemotherapy by ≥2 weeks. Secondary endpoints were event-free survival (EFS) and overall survival (OS).Thirty-five patients with a median age of 11 years were enrolled. The mean time to last dose of chemotherapy prior to LC was 12.6 ± 1.4 weeks and 45.5% of patients received intended chemotherapy without any delay prior to LC. There were no toxic deaths or unexpected toxicities. Five-year EFS was 79.6% (95% confidence interval [CI]: 61.8-89.7%) and 5-year OS was 88% (95% CI: 71.4-95.3%).The addition of VTc to standard therapy was tolerable with sufficient interval compression compared to historical standard 3-week cycles.

Published
2015

133. Abnormal Pulmonary Lymphatic Flow in Patients With Lymphatic Anomalies and Respiratory Compromise

Author

Itkin, Maxim, Rabinowitz, Deborah A., Nadolski, Gregory, Stafler, Patrick, Mascarenhas, Leo, and Adams, Denise

Abstract

Pulmonary involvement in lymphatic anomalies (LA) is associated with significant morbidity and mortality. Dynamic contrast-enhanced magnetic resonance lymphangiography (DCMRL) is capable of imaging the lymphatic system in a variety of pulmonary lymphatic disorders.

Published
2020
Full Text
View/download PDF

135. Sunitinib in pediatric patients with advanced gastrointestinal stromal tumor: results from a phase I/II trial.

Author

Verschuur, Arnauld C., Bajčiová, Viera, Mascarenhas, Leo, Khosravan, Reza, Lin, Xun, Ingrosso, Antonella, and Janeway, Katherine A.

Subjects
GASTROINTESTINAL stromal tumors, PROGRESSION-free survival
Abstract

Background: Sunitinib is approved for treatment of adults with imatinib-resistant gastrointestinal stromal tumor (GIST) or imatinib intolerance.Methods: This single-arm, multicenter, multinational phase I/II clinical trial (NCT01396148) enrolled eligible patients aged 6 to < 18 years with advanced, unresectable GIST with non-mutant KIT, or who demonstrated disease progression or intolerance to imatinib. Patients received sunitinib 15 mg/m2 per day, 4-weeks-on/2-weeks-off (schedule 4/2), for ≤ 18 cycles over 24 months. Intra-patient dose escalation to 22.5 and subsequently 30 mg/m2 were permitted based on individual patient tolerability and supported by real-time pharmacokinetics (PK). Primary objective was PK characterization. Secondary objectives included safety, antitumor activity and PK/pharmacodynamic relationships.Results: Six patients were enrolled with median (range) age of 14 (13-16) years. All six patients completed at least three treatment cycles, with one completing all 18 cycles. Five patients had a dose increase to 22.5 mg/m2; two of them had a further dose increase to 30 mg/m2. The average daily dose at cycle 3 was 21.1 mg/m2 (n = 6). Steady-state plasma concentrations were reached by day 15, cycle 1. No tumor responses were observed, but three patients had stabilization of the disease (50%). Median progression-free survival was 5.8 months (95% CI 2.3-not reached). There were no serious adverse events.Conclusions: The tolerable dose of sunitinib in chemotherapy-naïve pediatric patients is at least 20 mg/m2 on schedule 4/2. The safety profile and PK of sunitinib in pediatric patients with GIST are comparable to those in adults. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

136. Comparative Clinicopathologic and Genomic Analysis of Hepatocellular Neoplasm, Not Otherwise Specified, and Hepatoblastoma

Author

Zhou, Shengmei, Sarabia, Stephen F., Estrine, Dolores, Ostrow, Dejerianne, Schmidt, Ryan J., Warren, Mikako, Raca, Gordana, Shillingford, Nick, Wang, Larry, Pawel, Bruce, Stein, James E., Biegel, Jaclyn A., Lopez-Terrada, Dolores, Mascarenhas, Leo, and Ji, Jianling

Abstract

Accurate diagnosis and treatment of hepatocellular neoplasm, not otherwise specified (HCN-NOS), poses significant challenges. Our study aimed to investigate the clinicopathologic and genomic similarities and differences between HCN-NOS and hepatoblastoma (HB) to guide diagnostic and treatment strategies. The clinicopathologic characteristics of 16 patients with HCN-NOS and 23 patients with HB were compared. Molecular studies, including the OncoKids DNA- and RNA-based next-generation sequencing panel, chromosomal microarray, and targeted Sanger sequencing analyses of CTNNB1and TERTpromoters, were employed. We found that patients with HCN-NOS were older (P< .001) and more frequently classified as high risk (P< .01), yet they showed no significant differences in alpha fetoprotein levels or survival outcomes compared with those with HB. HCN-NOS and HB had a comparable frequency of sequence variants, with CTNNB1 mutations being predominant in both groups. Notably, TERTpromoter mutations (37.5%) and rare clinically significant variants (BRAF, NRAS, and KMT2D) were exclusive to HCN-NOS. HCN-NOS demonstrated a higher prevalence of gains in 1q, encompassing the MDM4locus (17/17 vs 11/24; P< .001), as well as loss/loss of heterozygosity (LOH) of 1p (11/17 vs 6/24; P< .05) and chromosome 11 (7/17 vs 1/24; P< .01) when compared with HB. Furthermore, the recurrent loss/LOH of chromosomes 3, 4p, 9, 15q, and Y was only observed in HCN-NOS. However, no significant differences were noted in gains of chromosomes 2, 8, and 20, or loss/LOH of 4q and 11p between the 2 groups. Notably, no clinically significant gene fusions were detected in either group. In conclusion, our study reveals that HCN-NOS exhibits high-risk clinicopathologic features and greater structural complexity compared with HB. However, patients with HCN-NOS exhibit comparable alpha fetoprotein levels at diagnosis, CTNNB1mutation rates, and survival outcomes when subjected to aggressive treatment, as compared with those with HB. These findings have the potential to enhance diagnostic accuracy and inform more effective treatments for HCN-NOS.

Published
2024
Full Text
View/download PDF

137. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial.

Author

UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - (SLuc) Service d'hématologie et d'oncologie pédiatrique, Marina, Neyssa M, Smeland, Sigbjørn, Bielack, Stefan S, Bernstein, Mark, Jovic, Gordana, Krailo, Mark D, Hook, Jane M, Arndt, Carola, van den Berg, Henk, Brennan, Bernadette, Brichard, Bénédicte, Brown, Ken L B, Butterfass-Bahloul, Trude, Calaminus, Gabriele, Daldrup-Link, Heike E, Eriksson, Mikael, Gebhardt, Mark C, Gelderblom, Hans, Gerss, Joachim, Goldsby, Robert, Goorin, Allen, Gorlick, Richard, Grier, Holcombe E, Hale, Juliet P, Hall, Kirsten Sundby, Hardes, Jendrik, Hawkins, Douglas S, Helmke, Knut, Hogendoorn, Pancras C W, Isakoff, Michael S, Janeway, Katherine A, Jürgens, Heribert, Kager, Leo, Kühne, Thomas, Lau, Ching C, Leavey, Patrick J, Lessnick, Stephen L, Mascarenhas, Leo, Meyers, Paul A, Mottl, Hubert, Nathrath, Michaela, Papai, Zsuzsanna, Randall, R Lor, Reichardt, Peter, Renard, Marleen, Safwat, Akmal Ahmed, Schwartz, Cindy L, Stevens, Michael C G, Strauss, Sandra J, Teot, Lisa, Werner, Mathias, Sydes, Matthew R, Whelan, Jeremy S, UCL - SSS/IREC/PEDI - Pôle de Pédiatrie, UCL - (SLuc) Service d'hématologie et d'oncologie pédiatrique, Marina, Neyssa M, Smeland, Sigbjørn, Bielack, Stefan S, Bernstein, Mark, Jovic, Gordana, Krailo, Mark D, Hook, Jane M, Arndt, Carola, van den Berg, Henk, Brennan, Bernadette, Brichard, Bénédicte, Brown, Ken L B, Butterfass-Bahloul, Trude, Calaminus, Gabriele, Daldrup-Link, Heike E, Eriksson, Mikael, Gebhardt, Mark C, Gelderblom, Hans, Gerss, Joachim, Goldsby, Robert, Goorin, Allen, Gorlick, Richard, Grier, Holcombe E, Hale, Juliet P, Hall, Kirsten Sundby, Hardes, Jendrik, Hawkins, Douglas S, Helmke, Knut, Hogendoorn, Pancras C W, Isakoff, Michael S, Janeway, Katherine A, Jürgens, Heribert, Kager, Leo, Kühne, Thomas, Lau, Ching C, Leavey, Patrick J, Lessnick, Stephen L, Mascarenhas, Leo, Meyers, Paul A, Mottl, Hubert, Nathrath, Michaela, Papai, Zsuzsanna, Randall, R Lor, Reichardt, Peter, Renard, Marleen, Safwat, Akmal Ahmed, Schwartz, Cindy L, Stevens, Michael C G, Strauss, Sandra J, Teot, Lisa, Werner, Mathias, Sydes, Matthew R, and Whelan, Jeremy S

Abstract

BACKGROUND: We designed the EURAMOS-1 trial to investigate whether intensified postoperative chemotherapy for patients whose tumour showed a poor response to preoperative chemotherapy (≥10% viable tumour) improved event-free survival in patients with high-grade osteosarcoma. METHODS: EURAMOS-1 was an open-label, international, phase 3 randomised, controlled trial. Consenting patients with newly diagnosed, resectable, high-grade osteosarcoma aged 40 years or younger were eligible for randomisation. Patients were randomly assigned (1:1) to receive either postoperative cisplatin, doxorubicin, and methotrexate (MAP) or MAP plus ifosfamide and etoposide (MAPIE) using concealed permuted blocks with three stratification factors: trial group; location of tumour (proximal femur or proximal humerus vs other limb vs axial skeleton); and presence of metastases (no vs yes or possible). The MAP regimen consisted of cisplatin 120 mg/m2, doxorubicin 37·5 mg/m2 per day on days 1 and 2 (on weeks 1 and 6) followed 3 weeks later by high-dose methotrexate 12 g/m2 over 4 h. The MAPIE regimen consisted of MAP as a base regimen, with the addition of high-dose ifosfamide (14 g/m2) at 2·8 g/m2 per day with equidose mesna uroprotection, followed by etoposide 100 mg/m2 per day over 1 h on days 1-5. The primary outcome measure was event-free survival measured in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT00134030. FINDINGS: Between April 14, 2005, and June 30, 2011, 2260 patients were registered from 325 sites in 17 countries. 618 patients with poor response were randomly assigned; 310 to receive MAP and 308 to receive MAPIE. Median follow-up was 62·1 months (IQR 46·6-76·6); 62·3 months (IQR 46·9-77·1) for the MAP group and 61·1 months (IQR 46·5-75·3) for the MAPIE group. 307 event-free survival events were reported (153 in the MAP group vs 154 in the MAPIE group). 193 deaths were reported (101 in the MAP group vs 92 in the MAPIE group). Event

Published
2016

138. Combined clinical and genetic risk prediction of central nervous system subsequent neoplasms (CNS SNs) in childhood cancer survivors (CCS): A report from the COG ALTE03N1 study.

Author

Wang, Xuexia, primary, Sun, Canlan, additional, Hageman, Lindsey, additional, Barnett, Kandice, additional, Desai, Sunil, additional, Hawkins, Douglas S., additional, Hudson, Melissa M., additional, Mascarenhas, Leo, additional, Neglia, Joseph Philip, additional, Oeffinger, Kevin C., additional, Ritchey, Arthur Kim, additional, Robison, Leslie L., additional, Villaluna, Doojduen, additional, Landier, Wendy, additional, and Bhatia, Smita, additional

Published
2016
Full Text
View/download PDF

139. 18F 2Fluoro-2deoxy-D-glucose positron emission tomography (FDG-PET) response to predict event-free survival (EFS) in intermediate risk (IR) or high risk (HR) rhabdomyosarcoma (RMS): A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group (COG).

Author

Harrison, Douglas James, primary, Parisi, Marguerite T, additional, Shulkin, Barry L., additional, Chi, Yueh-Yun, additional, Anderson, James Robert, additional, Mi, Xinlei, additional, Malempati, Suman, additional, Mascarenhas, Leo, additional, McCowage, Geoffrey Brian, additional, Weigel, Brenda, additional, Wolden, Suzanne L., additional, Yock, Torunn I., additional, Rodeberg, David A., additional, Hayes-Jordan, Andrea Anita, additional, Teot, Lisa A., additional, Spunt, Sheri L., additional, Meyer, William H., additional, and Hawkins, Douglas S., additional

Published
2016
Full Text
View/download PDF

141. Bronchial Mucoepidermoid Carcinoma With the Classic MAML2 Gene Rearrangement in a 2-year-old Boy.

Author

Szymanski, Linda J., Molas-Torreblanca, Kira, Bawab, Ramzi, Kim, Eugene, Don, Debra, Mascarenhas, Leo, Stanley, Phillip, Zhou, Shengmei, and Shillingford, Nick

Subjects
CARCINOMA, CHILDREN, WHEEZE, BRONCHOSCOPY, RADIOLOGY, BIOPSY, DIAGNOSIS
Abstract

Pulmonary mucoepidermoid carcinoma (PMEC) is rare. To date, primary PMEC has not been reported in a child younger than 3 years of age. We report a case of a 2-year-old boy who presented with 3 episodes of wheezing, cough, and fever over a period of 1 month. Radiologic findings were consistent with foreign body aspiration with consequent bronchial obstruction. Bronchoscopy was performed and attempts to retrieve the foreign body resulted in a biopsy of a fleshy lesion. By histology, the lesion was an epithelial neoplasm comprising cells arranged in a nested pattern. The neoplastic cells were round with round nuclei and amphophilic, vacuolated cytoplasm. Our diagnosis was low-grade salivary gland-type carcinoma of the bronchus. The pneumonectomy specimen showed a well-circumscribed, polypoid intrabronchial mass measuring 2.1 cm in greatest dimension. Histologic examination of the tumor showed an admixture of intermediate cells which were predominant, a small number of mucus cells and rare foci of squamous cells. The final diagnosis rendered was a low-grade mucoepidermoid carcinoma of the bronchus. Accurate diagnosis of PMEC can be challenging on limited biopsy material as seen in the case reported here. The use of molecular studies such as MAML2 gene rearrangement may facilitate diagnosis in difficult cases. Increased awareness of this entity and further molecular studies are needed for a better understanding of the pathogenesis of PMEC. To date, the reported age range for primary bronchial mucoepidermoid carcinoma is between 3 years and 78 years. This case represents the youngest patient reported in the English literature. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

142. Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children’s Oncology Group.

Author

Shulman, David S., Klega, Kelly, Imamovic-Tuco, Alma, Clapp, Andrea, Nag, Anwesha, Thorner, Aaron R., Van Allen, Eliezer, Ha, Gavin, Lessnick, Stephen L., Gorlick, Richard, Janeway, Katherine A., Leavey, Patrick J., Mascarenhas, Leo, London, Wendy B., Vo, Kieuhoa T., Stegmaier, Kimberly, Hall, David, Krailo, Mark D., Barkauskas, Donald A., and DuBois, Steven G.

Abstract

Background: New prognostic markers are needed to identify patients with Ewing sarcoma (EWS) and osteosarcoma unlikely to benefit from standard therapy. We describe the incidence and association with outcome of circulating tumour DNA (ctDNA) using next-generation sequencing (NGS) assays.Methods: A NGS hybrid capture assay and an ultra-low-pass whole-genome sequencing assay were used to detect ctDNA in banked plasma from patients with EWS and osteosarcoma, respectively. Patients were coded as positive or negative for ctDNA and tested for association with clinical features and outcome.Results: The analytic cohort included 94 patients with EWS (82% from initial diagnosis) and 72 patients with primary localised osteosarcoma (100% from initial diagnosis). ctDNA was detectable in 53% and 57% of newly diagnosed patients with EWS and osteosarcoma, respectively. Among patients with newly diagnosed localised EWS, detectable ctDNA was associated with inferior 3-year event-free survival (48.6% vs. 82.1%; p = 0.006) and overall survival (79.8% vs. 92.6%; p = 0.01). In both EWS and osteosarcoma, risk of event and death increased with ctDNA levels.Conclusions: NGS assays agnostic of primary tumour sequencing results detect ctDNA in half of the plasma samples from patients with newly diagnosed EWS and osteosarcoma. Detectable ctDNA is associated with inferior outcomes. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

144. Body mass index (BMI) at diagnosis is associated with surgical wound complications in patients with localized osteosarcoma: a report from the Children's Oncology Group

Author

Hingorani, Pooja, Seidel, Kristy, Krailo, Mark, Mascarenhas, Leo, Meyers, Paul, Marina, Neyssa, Conrad, Ernest U., and Hawkins, Douglas S.

Subjects
Adult, Male, Osteosarcoma, Young Adult, Postoperative Complications, Adolescent, Child, Preschool, Humans, Female, Child, Article, Body Mass Index
Abstract

Malnutrition is common at diagnosis and during treatment for sarcoma patients. Poor nutritional status is associated with increased risk of complications, particularly infections. We investigated the role of body mass index (BMI) on the incidence of surgical wound complications in patients with localized osteosarcoma treated on the Children's Oncology Group (COG) legacy trial, INT-0133.Patients considered in this report had localized osteosarcoma, enrolled on COG trial INT-0133, remained on protocol therapy to have definitive surgery 6-16 weeks after study entry, and had adequate height, weight, and surgical complication data for analysis. By protocol design, definitive surgical resection was planned for 10 weeks after induction chemotherapy. Wound complications within 30 days after definitive surgery were considered post-operative. BMI was calculated at the start of neoadjuvant chemotherapy and expressed as age- and gender-adjusted percentile. The incidence of wound complications was evaluated by logistic regression or Fisher's exact test.A total of 498 patients met criteria for analysis. Low BMI (≤10th percentile) was seen in 73 (14.7%), middle BMI (11th-94th percentile) in 382 (76.7%), and high BMI (≥95th percentile) in 43 (8.6%) patients. Wound infection or slough was seen in low BMI patients (OR = 2.0, P = 0.07) although the results did not reach statistical significance. Arterial thrombosis was more common in high BMI patients (OR = 9.4, P = 0.03).Abnormal BMI at the start of treatment for localized osteosarcoma is associated with increased risk of post-operative wound complications such as arterial thrombosis. Future studies should evaluate whether maintenance of age-appropriate BMI reduces the risk of surgical complications.

Published
2010

145. Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies

Author

Reed, Damon R., primary, Mascarenhas, Leo, additional, Manning, Kathleen, additional, Hale, Gregory A., additional, Goldberg, John, additional, Gill, Jonathan, additional, Sandler, Eric, additional, Isakoff, Michael S., additional, Smith, Tiffany, additional, Caracciolo, Jamie, additional, Lush, Richard M., additional, Juan, Tzu‐Hua, additional, Lee, Jae K., additional, Neuger, Anthony M., additional, and Sullivan, Daniel M., additional

Published
2015
Full Text
View/download PDF

146. 6-Mercaptopurine (6MP) Intake during Maintenance for Childhood Acute Lymphoblastic Leukemia (ALL) - a Comparison of Self-Report and Electronic Monitoring: A Report from the Children's Oncology Group (COG) Study AALL03N1

Author

Landier, Wendy, primary, Chen, Yanjun, additional, Hageman, Lindsey, additional, Kim, Heeyoung, additional, Bostrom, Bruce C., additional, Casillas, Jacqueline, additional, Dickens, David, additional, Evans, William E., additional, Maloney, Kelly W., additional, Mascarenhas, Leo, additional, Ritchey, Arthur K., additional, Termuhlen, Amanda M., additional, Carroll, William L., additional, Wong, F. Lennie, additional, Relling, Mary V., additional, and Bhatia, Smita, additional

Published
2015
Full Text
View/download PDF

147. Pilot Study of Adding Vincristine, Topotecan, and Cyclophosphamide to Interval-Compressed Chemotherapy in Newly Diagnosed Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group

Author

Mascarenhas, Leo, primary, Felgenhauer, Judy L., additional, Bond, Mason C., additional, Villaluna, Doojduen, additional, Femino, Joseph Dominic, additional, Laack, Nadia N., additional, Ranganathan, Sarangarajan, additional, Meyer, James, additional, Womer, Richard B., additional, Gorlick, Richard, additional, Krailo, Mark D., additional, and Marina, Neyssa, additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results